Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 330Breast Neoplasms 185Lung Neoplasms 177Ovarian Neoplasms 156Triple Negative Breast Neoplasms 88Fallopian Tube Neoplasms 75Squamous Cell Carcinoma of Head and Neck 74Small Cell Lung Carcinoma 67Esophageal Neoplasms 55Neoplasms 49Head and Neck Neoplasms 47Carcinoma, Ovarian Epithelial 44Uterine Cervical Neoplasms 36Esophageal Squamous Cell Carcinoma 36Endometrial Neoplasms 35Prostatic Neoplasms 33Neoplasm Metastasis 32Lymphoma, Large B-Cell, Diffuse 32Recurrence 31Adenocarcinoma of Lung 31Lymphoma 30Brain Neoplasms 29Neuroblastoma 24Central Nervous System Neoplasms 24Retinoblastoma 23Lymphoma, Non-Hodgkin 23Carcinoma, Squamous Cell 23Hodgkin Disease 20Testicular Neoplasms 19Urinary Bladder Neoplasms 16

Interventions

pembrolizumab 2enfortumab vedotin 2Gemcitabine 2Cisplatin 2sacituzumab govitecan 1erdafitinib 1avelumab 1Vinblastine 1Paclitaxel 1Nivolumab 1Methotrexate 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Muscle Invasive Bladder Urothelial Carcinoma × Carboplatin × Clear all
NCT06204614 2026-05-18

Drug Screening Using IMD in Bladder Cancer

Brigham and Women's Hospital

Phase EARLY_PHASE1 Enrolling by invitation
18 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡